Testing Algorithms for the Diagnosis of Malignant Glandular Tumors of the Uterine Cervix Histotyped per the International Endocervical Adenocarcinoma Criteria and Classification (IECC) System

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Máire A. Duggan ◽  
Qiuli Duan ◽  
Ruth M. Pfeiffer ◽  
Mary Anne Brett ◽  
Sandra Lee ◽  
...  
Keyword(s):  
Uterine Cervix ◽  
Endocervical Adenocarcinoma ◽  
Testing Algorithms

Mucinous Expression in Benign and Neoplastic Glandular Lesions of the Uterine Cervix

2006 ◽  
Vol 130 (10) ◽  
pp. 1510-1515 ◽  
Author(s):  
Allyson C. Baker ◽  
Isam Eltoum ◽  
Rebecca O. Curry ◽  
Cecil R. Stockard ◽  
Upender Manne ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Uterine Cervix ◽  
Adenosquamous Carcinoma ◽  
Adenocarcinoma In Situ ◽  
Endocervical Adenocarcinoma ◽  
Mucin Expression ◽  
The Difference ◽  
Almost All ◽  
Endometrial Carcinomas

Abstract Context.—Mucins are glycoproteins produced by both normal and neoplastic glandular epithelial cells including endocervix. Objective.—To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions. Design.—Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix. The presence of any staining was considered positive. Results.—All benign endocervical epithelia, including tubal metaplasia and microglandular hyperplasia, expressed MUC1, MUC4, and MUC5AC but not MUC2. Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix. MUC2 staining was noted in 25%, 40%, and 22% of AIS, endocervical adenocarcinomas, and endometrial adenocarcinomas, respectively. About 38% of AIS, 75% of endocervical adenocarcinomas, and 44% of endometrial adenocarcinomas expressed MUC4. Half of AIS, most of endocervical adenocarcinomas, and 22% of endometrial adenocarcinomas expressed MUC5AC. The difference in MUC4 and MUC5AC expression between benign endocervical lesions and AIS and the difference in MUC5AC expression between endocervical and endometrial neoplasms were statistically significant. Conclusions.—Mucin expressions differed among benign endocervical lesions and AIS and among endocervical and endometrial malignancies. These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.

Immunohistochemical characterization of endocervical papillary serous carcinoma

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 286-292 ◽  
Author(s):  
S. Nofech-Mozes ◽  
G. Rasty ◽  
N. Ismiil ◽  
A. Covens ◽  
M. A. Khalifa
Keyword(s):  
Carcinoembryonic Antigen ◽  
Uterine Cervix ◽  
Serous Carcinoma ◽  
Control Group ◽  
Fallopian Tubes ◽  
Endocervical Adenocarcinoma ◽  
Conventional Cell ◽  
Papillary Serous Carcinoma ◽  
Histologic Subtypes

Endocervical adenocarcinomas are rare and aggressive neoplasms. Papillary serous endocervical adenocarcinomas are the rarest form of endocervical adenocarcinomas. This tumor exhibits morphologic similarities to its counterparts commonly seen in the endometrium, fallopian tubes, ovaries, and peritoneum, which are known to have an aggressive behavior. Because of the rarity of this tumor, little is known about its immunophenotyping. In this study, we included ten cases of papillary serous carcinomas arising from the uterine cervix (PSCC) diagnosed in the absence of a primary endometrial malignancy. We studied their immunohistochemical profile, using a panel of antibodies against Ki67, bcl-2, p53, carcinoembryonic antigen (CEA), and CD10, and compared them to 20 consecutive cases of cervical adenocarcinoma of conventional cell subtypes (CAC) (15 mucinous, 3 adenosquamous, and 2 endometrioid). Immunostaining was recorded semiquantitatively. Patients with PSCC ranged in age from 27 to 79 years (mean = 51.6 ± 19.1), while the conventional cell subtypes control group were 28–90 years old (mean = 47.5 ± 16.9). Only p53 and CEA immunostaining significantly correlated with the PSCC morphology (P= 0.001 and P= 0.016, respectively) as shown by Cochran–Mantel–Haenszel Statistics (Modified Ridit Scores). PSCC is a distinctive immunophenotypic subtype of endocervical adenocarcinoma with significantly higher p53 and lower CEA reactivity than other more common histologic subtypes.

scholarly journals So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature

2021 ◽  
pp. 1792-1798
Author(s):  
Ruth Gabriela Herrera Gómez ◽  
Delfyne Hastir ◽  
Aikaterini Liapi ◽  
Ana Dolcan ◽  
Fernanda G. Herrera ◽  
...  
Keyword(s):  
Uterine Cervix ◽  
Parp Inhibitor ◽  
Serous Carcinoma ◽  
Review Of The Literature ◽  
Endocervical Adenocarcinoma ◽  
Mutational Status ◽  
Targeted Treatments ◽  
Stage Ivb ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing

Serous carcinoma of the uterine cervix (SCUC) is now believed to be a morphological variant of an HPV-associated endocervical adenocarcinoma or a metastasis from a serous carcinoma of the upper tract. In terms of mutational status as detected by next-generation sequencing (NGS), this controversial entity has not been characterized yet. We describe the case of a patient with a carcinoma categorized as stage IVB SCUC, initially treated with carboplatin, paclitaxel, and bevacizumab, followed by maintenance with bevacizumab. After locoregional progression, radiotherapy was administered. Unfortunately, further progression was observed, and carboplatin was resumed. Considering the presence of a <i>BRCA2</i> mutation as detected by NGS, treatment with a PARP inhibitor (olaparib) was decided and allowed disease control for 6 months. We believe that <i>BRCA</i> mutation may be systematically searched in patients suffering from carcinomas formerly referred to as SCUC and that targeted treatments should be considered.

scholarly journals Gastric type mucinous endocervical adenocarcinoma of the uterine cervix: very rare and interesting case

2018 ◽  
Vol 61 (1) ◽  
pp. 165 ◽  
Author(s):  
Chul Min Park ◽  
Hyun Min Koh ◽  
Soyun Park ◽  
Hye Sim Kang ◽  
Soon Sup Shim ◽  
...  
Keyword(s):  
Uterine Cervix ◽  
Interesting Case ◽  
Endocervical Adenocarcinoma ◽  
Gastric Type

Magnetic Resonance Appearance of Gastric-Type Adenocarcinoma of the Uterine Cervix in Comparison With That of Usual-Type Endocervical Adenocarcinoma: A Pitfall of Newly Described Unusual Subtype of Endocervical Adenocarcinoma

2014 ◽  
Vol 24 (8) ◽  
pp. 1474-1479 ◽  
Author(s):  
Aki Kido ◽  
Yoshiki Mikami ◽  
Takashi Koyama ◽  
Masako Kataoka ◽  
Fuki Shitano ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Mr Imaging ◽  
Uterine Cervix ◽  
Growth Pattern ◽  
Cervical Canal ◽  
Imaging Features ◽  
Characteristic Appearance ◽  
Usual Type ◽  
Endocervical Adenocarcinoma ◽  
Gastric Type

ObjectiveThe aim of this study was to evaluate the characteristics of gastric-type adenocarcinoma (GAS) of the uterine cervix, compared with usual-type endocervical adenocarcinoma (UEA) and squamous cell carcinoma (SCC), using magnetic resonance (MR) imaging.Materials and MethodsA total of 15 histopathologically defined GASs, 12 UEAs, and 40 SCCs were retrieved from archive files and were included for evaluation. Microscopic features, as well as topography and tumor growth pattern, and presence or absence of coexistence of cystic cavities were evaluated. Accuracy of evaluation for parametrial tissue and vaginal wall invasion was also evaluated by 2 diagnostic radiologists, independently, without clinical information on cases.ResultsThirteen (86.70%) of the 15 cases of GAS exhibited tumors in the higher portion of cervical canal or the entire cervix. On the other hand, SCCs and UEAs were mainly located in the lower portion of cervical canal, at a frequency of 21 of 40 (52.5%) and 9 of 12 (75.0%), respectively. Involvement of the corpus was observed more frequently in cases of GAS with an occurrence of 8 of 15 (53.3%), whereas in all cases of UEA and in 5 of the 40 cases of SCC, the corpus was free of tumor. In GAS cases, the predominant pattern of growth was highly infiltrating and endophytic (14/15, 93.3%), whereas an exophytic growth pattern was observed in 31 (77.5%) of the 40 SCC cases and 11 (91.7%) of the 12 UEA cases. Cystic cavities associated with tumors were identified in only 1 case of SCC but occurred in 12 (80.0%) of the 15 GASs and 4 (33.3%) of the 12 UEAs. Diagnostic accuracies of more than 70% and more than 60% were reached in parametrial invasion and vaginal invasion, respectively, in GAS.ConclusionDistinctive MR imaging features of GAS were infiltrating mass of endophytic growth, location in the upper cervical canal, and association with tiny cysts. This characteristic appearance can be a clue for the evaluation of extent of tumor based on MR imaging.

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group

2018 ◽  
Vol 28 (1) ◽  
pp. 99-106 ◽  
Author(s):  
Atsumi Kojima ◽  
Muneaki Shimada ◽  
Yoshiki Mikami ◽  
Shoji Nagao ◽  
Nobuhiro Takeshima ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Uterine Cervix ◽  
Mucinous Carcinoma ◽  
Stage Ii ◽  
World Health ◽  
Serous Carcinoma ◽  
Endocervical Adenocarcinoma ◽  
Alternative Treatment Strategy ◽  
Gastric Type

ObjectiveGastric-type mucinous carcinoma (GAS) is a novel variant of mucinous carcinoma of the uterine cervix, characterized by aggressive clinical behavior and absence of high-risk human papillomavirus. We conducted this study to evaluate the chemosensitivity of GAS compared with that of usual-type endocervical adenocarcinoma (UEA) in patients who had been enrolled in our previous study.MethodsOf 52 patients from our previous phase 2 study (SGSG005) of neoadjuvant chemotherapy with docetaxel and carboplatin for stage IB2 to IIB nonsquamous cervical cancer, 47 (stage IB2, 12; stage IIA2, 7; stage IIB, 28) were enrolled in this study with written informed consent. The biopsy specimens before neoadjuvant chemotherapy and surgical specimens after chemotherapy were centrally reviewed based on the updated World Health Organization classification (2014).ResultsOf 47 patients with nonsquamous cell carcinoma, 20 (42.6%) were diagnosed with UEA, 13 (27.7%) with GAS, 12 (25.5%) with adenosquamous carcinoma, and 1 patient each (2%) with small cell carcinoma and serous carcinoma. Consequently, 33 patients, consisting of 20 patients with UEA and 13 patients with GAS, were eligible for the current study. The response rate of GAS was significantly lower than that of UEA (46.2% vs 85.0%, P = 0.048). Of 16 cases of stage II UEA, 11 (68.8%) were downstaged on microscopic examination of postsurgical specimens, but none of the 8 patients with stage II GAS showed any response (P < 0.01). Two inoperative tumors were GAS. With a median follow-up duration of 56 months, the 5-year progression-free and overall survival rates of GAS were significantly worse than those of UEA (38.5% vs 75.0% [P = 0.011] and 36.9% vs 90.0% [P < 0.001], respectively).ConclusionsThese findings suggest that GAS should be distinguished from UEA by its chemoresistance, necessitating an alternative treatment strategy established for this distinct subtype of endocervical adenocarcinoma.

Sign in / Sign up

Export Citation Format

Share Document